HomeInsightsStock Comparison

Dr Reddys Laboratories Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Dr Reddys Laboratories Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Last Updated on: Jun 13, 2025

Key Highlights

  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1363 as of 12 Jun 15:30.
  • The P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 22.5 on March 2020 to 40.6 on March 2024 . This represents a CAGR of 12.53% over 5 years.
  • The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 388812 crore on March 2024 . This represents a CAGR of 35.70% over 5 years.
  • The revenue of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 9056 crore as compare to the Dec '24 revenue of ₹ 8535 crore. This represent the growth of 6.1% The revenue of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 13571 crore as compare to the Dec '24 revenue of ₹ 14141 crore. This represent the decline of -4.03%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 2525 crore as compare to the Dec '24 ebitda of ₹ 2427 crore. This represent the growth of 4.04% The ebitda of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 3967 crore as compare to the Dec '24 ebitda of ₹ 4158 crore. This represent the decline of -4.6%.
  • The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1586 crore over 8 quarters. This represents a CAGR of 6.27% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2013 crore to ₹ 2160 crore over 8 quarters. This represents a CAGR of 3.60% .
  • The Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 29.89 % on March 2020 to 113.33 % on March 2024 . This represents a CAGR of 30.55% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Sun Pharmaceuticals Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys Laboratories Ltd up for third consecutive session

Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting ...

Read more

12 Jun 2025 13:05

News

Dr Reddys Laboratories Ltd soars 0.07%, up for fifth straight session

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting...

Read more

09 Jun 2025 13:00

News

Alvotech and Dr Reddy's enter into collaboration and license agreement for pembrolizumab

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manu...

Read more

05 Jun 2025 09:20

News

Dr Reddys Lab gains on global biosimilar deal with Alvotech

Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $...

Read more

05 Jun 2025 10:10

News

Dr Reddys Laboratories allots 57,840 equity shares under ESOS

Dr Reddys Laboratories has allotted 57,840 equity shares of Re.1/- each of the Company, fu...

Read more

03 Jun 2025 16:28

News

Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA

In a regulatory filing made on Saturday (24 May 2025), the company informed that the US FD...

Read more

26 May 2025 09:33

Sun Pharmaceutical Industries Ltd News Hub

News

Board of Sun Pharmaceutical Industries appoints director

The Board of Sun Pharmaceutical Industries at its meeting held on 22 May 2025 has approved...

Read more

23 May 2025 11:13

News

Sun Pharmaceutical Industries announces cessation of director

The Board of Sun Pharmaceutical Industries at its meeting held on 22 May 2025 has noted th...

Read more

23 May 2025 11:14

News

Sun Pharma drops after Q4 PAT slides 19% YoY to Rs 2,1450 cr

Profit before tax (PBT) jumped 15.6% YoY to Rs 3,254.35 crore in Q4 FY25. During the quart...

Read more

23 May 2025 13:48

News

Sun Pharmaceuticals Industries AGM scheduled

Sun Pharmaceuticals Industries announced that the 33th Annual General Meeting(AGM) of the ...

Read more

23 May 2025 15:37

News

Board of Sun Pharmaceuticals Industries recommends final dividend

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its...

Read more

22 May 2025 20:47

News

Sun Pharmaceutical Industries Ltd Spurts 2.83%, BSE Healthcare index Rises 1.26%

Sun Pharmaceutical Industries Ltd rose 2.83% today to trade at Rs 1733.95. The BSE Healthc...

Read more

13 May 2025 09:30

SWOT Analysis Of Sun Pharmaceutical Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Sun Pharmaceuticals Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Dr Reddys Laboratories Ltd is 113,756 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 404,767 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd?

As of June 13, 2025, the Dr Reddys Laboratories Ltd stock price is INR ₹1363.15. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1687.0.

How do dividend payouts of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions